Bradley G. Somer

REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

Donald E. Tsai, Christine Hardy, John E. Tomaszewski et al. · Transplantation · 2001 · 363 citations

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park et al. · European Journal of Cancer · 2014 · 356 citations

Untreated Metastatic Adenocarcinoma, Oncology, Pancreatic Cancer +8

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Robert J. Motzer, Eric Jonasch, M. Dror Michaelson et al. · Journal of the National Comprehensive Cancer Network · 2019 · 289 citations · Full text

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Robert J. Motzer, Eric Jonasch, Shawna Boyle et al. · Journal of the National Comprehensive Cancer Network · 2020 · 247 citations · Full text

Urology, Genitourinary Cancer, Stage Iv Rcc +8